Introduction {#s1}
============

This report is the 11th annual European Society of Human Reproduction and Embryology (ESHRE) publication on European data on assisted reproductive technology (ART). The 10 previous reports, also published in Human Reproduction ([@DES023C5],[@DES023C6], [@DES023C7], [@DES023C8], [@DES023C9], [@DES023C10], [@DES023C11], [@DES023C12]; [@DES023C16]; [@DES023C3]), covered treatment cycles from 1997 to 2006. As in the last report, the printed version contains the four most important tables. Additional tables are available online, making the whole report consistent with those from previous years. In the published report, these tables will be referred as '[Supplementary data, Tables SI--SXVIII](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1)'. The main results of this report were presented at the annual ESHRE congress in Rome, July 2010.

Materials and Methods {#s2}
=====================

Data collection {#s2a}
---------------

Data on ART have been collected from 33 European countries, covering IVF, ICSI, frozen embryo replacement (FER), egg donation (ED), *in vitro* maturation (IVM), pooled data on preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS) and frozen oocyte replacements (FOR). In addition to ART, data on intrauterine inseminations using husband/partner\'s semen (IUI-H; 22 countries, 2 more than in 2006) and donor semen (IUI-D; 18 countries, as in 2006) were also included. The report includes treatments started between the 1 January and the 31 December 2007. Follow-up data on pregnancies and deliveries are cohort data, based on the reported cycles.

The forms were the same as in 2006, making all tables comparable. As in previous years, data were directly entered in ESHRE\'s computer system by each country co-ordinator, through software developed by ESHRE. Data analysis was performed in ESHRE headquarters by V. Goossens.

Results {#s3}
=======

Participation {#s3a}
-------------

The present report includes data from an additional country (Bosnia) (Table [I](#DES023TB1){ref-type="table"}). The proportion of reporting clinics (86%, 1029 out of 1204 clinics, listed in [Supplementary data](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1)) was the same as in 2006. In 18 countries, the coverage, as in 2006, reached 100%. Two countries (Ireland and Switzerland) were able to report data from all but a single Centre, but participation was limited (25--50%) in six others (Bosnia, Bulgaria, Hungary, Lithuania, Poland and Serbia) and very low (≤25% of clinics) in Greece and Latvia. Table IART in European countries in 2007. IVF clinics in the countryTreatment cyclesCycles/million\*TotalReportingIVFICSIFEREDIVMPGDFORAllWomen 15--45 years of agePopulationAlbania31667916161Austria262611724050306055283252674Belgium1818385212 357749975124 45912 2302352Bosnia52311310162Bulgaria1575747087980001369Cyprus754828231551122161590Czech Republic2424194772254169122149815 06068451476Denmark232360544981266814011111314 067140672558Finland181829311793352931423253208935111691718France10410420 21131 63514 7727428812467 57253631061Germany11811811 81133 37117 14062 3223944756Greece38982913601939259152503Hungary10559418436204806173128Iceland112151742443200066511 0832217Ireland76176810966929003565Italy202202879231 213709299443 7083834751Latvia41104751136000352Lithuania4218119846425Macedonia335044752910082520504Montenegro22252532782780397Norway111128052794225002200787187461711Poland38172374639223834751037515Portugal2222153629605241010115052362380494Russia695512 5689269308413672993821426 983Serbia126670450611 26Slovenia33885199752170162342885701714Spain182111347631 0239089798528278523454 620Sweden161654234768450028168315 06188591673Switzerland262510383465331200007815The Netherlands131391137050353619 69959691187Turkey929278534 60135 3861944473Ukraine18111848209857934502904899United Kingdom707018 23417 6888549174725437846 6883735763All12041029120 761256 64291 14515 73166046383607493 1844286879[^2][^3][^4][^5][^6]

Number of treatment cycles {#s3b}
--------------------------

In total, 493 184 cycles were reported, 34 425 more than in 2006 (+7.5%). Among the 377 403 fresh cycles (+7.8%), 120 761 were IVF (+2.9%) and 256 642 ICSI (+10.3%). The proportion of ICSI thus reached 68.0% of 'fresh' ART cycles (66.5% in 2006). The proportion of FER cycles compared with 'fresh' cycles was 24.2%---a figure comparable to the figure of 2006 (24.6%). The number of ED cycles, reported by 22 countries, increased more than that observed in fresh IVF/ICSI cycles, reaching 15 731 (+24.4%), the main contributor being Spain (7985 cycles, +22%). PGD was reported by 14 countries, with fewer cycles (4638, −29.3%) recorded in 2007. The main reason was absence of data from Turkey, who contributed 2308 cycles in 2006. Higher rates of IVM were reported (660, +267% compared with 2006). Finally, 3607 FOR cycles were reported (+1.0%), the majority from Italy (*n*= 2994). Table [I](#DES023TB1){ref-type="table"} also shows the number of cycles per million women of reproductive age (15--45 years) and per million inhabitants, in the 18 countries where data coverage was 100%. The highest availability of ART cycles was reported from Nordic countries, particularly in Denmark (14 067 and 2558), followed by Belgium, Finland, Iceland, Sweden, Norway and Slovenia, all of which provided over 8000 per million women aged 15--45 years and 1700 cycles per million inhabitants, respectively. More details are reported in [Supplementary data, Table SI](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1).

Reporting methods and size of the clinics {#s3c}
-----------------------------------------

Among the 18 countries with complete reporting ([Supplementary data, Table SII](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1)), the register was compulsory for 14 \[10 held by a National Health Authority (NHA) 3 by a medical organization (MO) and 1 by personal initiative\] and voluntary for 4 (three held by a MO and one by a NHA). Only seven registers were based on individual forms, i.e. cycle by cycle.

Among the 15 countries with partial coverage, 6 were held by an NHA/NGO and 3 were based on individual forms.

The distribution of clinics according to the number of cycles varied considerably among the countries ([Supplementary data, Table SIII](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1)). For example, in Italy 44.1% of the clinics provided fewer than 100 cycles annually, whereas in Belgium and in the Netherlands 61% of the clinics performed more than 1000 cycles a year.

Pregnancies and deliveries after treatment {#s3d}
------------------------------------------

Table [II](#DES023TB2){ref-type="table"} shows pregnancy and delivery rates per aspiration for IVF, ICSI and FER. Three countries provided outcome only per embryo transfer, while three did not provide data on deliveries. Thus the mean pregnancy rate and delivery rate were computed for countries providing the relevant information. There were huge variations across the countries. On average, pregnancy rates were 29.1% (+0.1% compared with 2006) and 28.6% (−1.3%) per aspiration for IVF and ICSI, and 20.1% per thawing for FER (+1.0%). Mean delivery rates per aspiration (per thawing for FER) were 21.1, 20.2 and 13.5%, respectively (−0.4, +1.8 and +0.8%). The detailed numbers of cycles, aspirations, transfers, pregnancies, deliveries and the corresponding rates per technique are reported in [Supplementary data, Table SIV](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1) for IVF, [Supplementary data, Table SV](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1) for ICSI and [Supplementary data, Table SVI](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1) for FER. Table IIResults after ART in 2007.CountryCycles IVF + ICSIIVFICSIFERART infants^a^ART infants per national births (%)AspirationsPregnancies per aspiration (%)Deliveries per aspiration (%)AspirationsPregnancies per aspiration (%)Deliveries per aspiration (%)Thawings FERPregnancies per thawing (%)Deliveries per thawing (%)Albania1456540.033.87837.229.564Austria522230630.7Belgium385229.822.412 35728.420.6749915.311.349254.1Bosnia1622832.114.311419.312.319Bulgaria128253233.825.667531.625.87915.28.9378Cyprus130545739.279240.20.015523.9Czech Republic416923.515.9Denmark11 035581926.121.3495226.021.3266816.513.531564.9Finland4724283027.320.6175927.922.4347521.216.018753.2France20 21124.619.231 63525.920.514 7101.8Germany45 18210 99529.416.032 12428.216.117 14018.39.910 4831.5Greece218978036.826.5129532.824.219322.814.0764Hungary243754427.421.5178728.222.862023.113.2776Iceland21525.121.917428.223.01683.7Ireland2864146633.927.497429.026.369222.415.5958Italy40 005757022.015.228 07522.014.370914.78.365751.2Latvia17910442.37529.31137.120LithuaniaMacedonia97949130.324.246129.121.02931.020.72871.2Montenegro2782420.820.824622.820.3660.8Norway5599268530.226.1270327.323.2225019.716.01509Poland487622033.228.2454735.429.0223820.916.02164Portugal4496132930.623.7269227.920.452416.411.811861.2Russia21 83712 17135.224.1900233.120.4308423.914.97197Serbia112064824.517.342634.529.8277Slovenia288284433.925.7193228.523.752118.814.29134.6Spain34 499304134.627 90533.6908923.112 647Sweden10 191501132.024.7450028.422.4450023.217.232603.1Switzerland450388628.120.9323527.420.1331218.712.61467The Netherlands16 163839927.620.5665931.825.146162.5Turkey78534 60152620.5Ukraine3946179040.329.8202837.430.957929.222.81812United Kingdom35 9221594430.126.417 61531.127.5854920.918.113 8381.8All^b^264 022108 39029.121.1199 95028.620.27249320.113.596 6901.5[^7][^8][^9][^10][^11][^12][^13]

In total, 96 690 babies were recorded as having been born in the 29 countries where the reporting from IVF, ICSI and FER included newborns (+8185). In countries with complete reporting, the percentage of babies conceived through ART varied from 0.5% of the national births in Turkey to 4.9% in Denmark. More details are provided in [Supplementary data, Table SI](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1), showing that the percentage of ART babies was above 3.0% in most of the Nordic countries, whereas this percentage was between 1.2 and 1.8% in the largest European countries (Germany, France, UK and Italy).

ED was reported by 22 countries ([Supplementary data, Table SVII](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1)). In total, 6628 clinical pregnancies (+1112) resulted from 143 34 embryo transfers (+1649), with pregnancy rates of 46.2% per transfer versus 43.5% in 2006. The mean delivery rate was 30.8% per transfer (*n*= 4448) in the 21 countries reporting deliveries.

Age distribution {#s3e}
----------------

The age distribution of women treated with IVF varied across countries ([Supplementary data, Table SVIII](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1)). In four countries, more than 20% of women were aged 40 years or more (Greece, Ireland, Italy and Switzerland), whereas it was \<5% in Albania, Poland and Slovenia. As expected, pregnancy rates decreased with age, from 34.0% through 26.5--13.9% for women aged ≤34, 35--39 years and ≥40 years, respectively, and the same trend was seen for delivery rates (26.2, 19.5 and 9.2%, respectively). Similar findings were found for ICSI ([Supplementary data, Table SIX](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1)). For FER ([Supplementary data, Table SX](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1)), only 12.6% of women were aged 40 years or more at transfer. In ED ([Supplementary data, Table SXI](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1)), the recipient was aged 40 years or more in 55.3% of cases on average, and only a few countries had a proportion lower than 50%: Albania (37.5%), Belgium (41.3%), Denmark (35.0%), Hungary (31.6%), Serbia (33.3%), Sweden (9.2%) and Ukraine (44.1%). Pregnancy and delivery rates in oocyte recipients were comparable across different age groups.

Number of embryos transferred and multiple deliveries {#s3f}
-----------------------------------------------------

Table [III](#DES023TB3){ref-type="table"} shows the number of embryos transferred after IVF and ICSI combined. The total percentage of single embryo transfers (SETs) was 21.4% (22.1% in 2006), double embryo transfers (DETs) 53.4% (57.3% in 2006), triple embryo transfers 22.7% (19.0% in 2006) and four or more embryo transfers 2.5% (1.6% in 2006). Information about numbers of elective single transfers is not yet available. As indicated in this table, major differences were seen between countries. In 2007, several countries reported a high number of SETs. The highest levels were found in Sweden (69.9%), Finland (57.8%) and Belgium (50.2%). The proportion of triple embryo transfers ranged from zero in Sweden to 58.6% in Greece. Transfer of four or more embryos ranged from zero in 10 countries and \<1% in 3 to 18.3% in Macedonia. Table IIINumber of embryos transferred and deliveries after ART in 2007.CountryIVF + ICSIFERTransfers1 embryo (%)2 embryos (%)3 embryos (% )4 + embryos (%)DeliveriesTwin (%)Triplet (%)DeliveriesTwin (%)Triplet (%)Albania13125.229.044.31.54517.82.2Austria491220.368.79.81.2Belgium14 87650.239.68.41.7338611.80.384513.10.1Bosnia12349.613.825.211.4185.60.0Bulgaria11268.335.644.211.931014.81.6714.30.0CyprusCzech Republic2711662Denmark922639.655.74.50.1229816.60.136114.10.0Finland413157.841.90.30.097711.30.25609.60.2France44 45323.262.313.21.310 35918.90.4191311.30.2Germany41 61512.566.920.60.0695021.20.6170215.10.6Greece185211.919.358.610.352125.70.8273.70.0Hungary214610.145.335.78.952422.52.18218.30.0Iceland32246.646.07.50.08717.20.05012.00.0Ireland222113.677.49.00.065824.30.910717.80.0Italy30 78020.430.549.10.0515820.62.8596.81.7Latvia17315.053.831.20.0LithuaniaMacedonia75023.926.930.918.321626.41.4633.30.0Montenegro25814.332.241.112.45516.41.8Norway4821132413.40.3361Poland433816.667.915.10.4138220.30.635912.80.0Portugal358517.469.213.30.286321.60.96217.70.0Russia19 51016.259.619.84.4452626.01.546017.21.7Serbia91113.377.16.92.72398.83.3Slovenia246227.669.72.60.067423.00.0746.80.0Spain27 155599027.10.7109217.30.4Sweden852969.930.10.00.022464.60.17766.70.1Switzerland373112.865.321.90.083018.90.541712.00.7The Netherlands13 375339615.10.162911.00.0Turkey31 80811.524.152.811.7372732.94.1Ukraine351011.344.233.111.4116025.01.613222.70.0United Kingdom31 11412.882.34.90.0909424.10.3154817.60.3All\*263 68121.453.422.72.56361721.31.01121213.10.3[^14]

In fresh cycles, the percentages of multiple deliveries were 21.3% for twins (19.9% in 2006) and 1.0% for triplets (0.9% in 2006). After FER, the percentages were 13.1% for twin deliveries (13.4% in 2006) and 0.3% for triplets (0.4% in 2006). Additional data on pregnancy outcome, singleton and multiple deliveries are provided in [Supplementary data, Table SXII](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1) (for fresh cycles) and [Supplementary data, Table SXIII](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1) for FER.

Risks and fetal reductions {#s3g}
--------------------------

[Supplementary data, Table SXIV](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1) shows the risk of preterm deliveries according to the number of newborn. Data were available from 15 countries. It shows that the risk of extreme preterm birth (gestational Week 20--27) increases from 1.0% for a singleton delivery, to 3.2% for twins and 11.8% for triplets. The same trend was noted for very preterm (28--32 weeks), from 2.7 to 11.1 and 35.7%, respectively, and for preterm (33--36 weeks), from 9.2 to 38.3 and 44.5%, respectively.

Ovarian hyperstimulation syndrome (OHSS) was reported in 26 of the 33 countries ([Supplementary data, Table SXV](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1)). In total, 2470 cases of OHSS were recorded, corresponding to a risk of OHSS of 0.7% in those countries (0.8% in 2006) of all stimulated cycles. [Supplementary data, Table SXV](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1) also includes other adverse outcomes, such as fetal reductions (*n*= 364).

Preimplantation genetic diagnosis/preimplantation genetic screening {#s3h}
-------------------------------------------------------------------

PGD/PGS activity was recorded from 14 countries (Table [I](#DES023TB1){ref-type="table"}) and involved 4638 cycles, 4274 aspirations, 2882 embryo transfers and 706 deliveries (16.5% per aspiration), the main contributors being Spain (2785 cycles).

*In vitro* maturation {#s3i}
---------------------

IVM was recorded in 11 countries, three more than in 2006 (Table [I](#DES023TB1){ref-type="table"}). A total of 660 aspirations (241 in 2006) were recorded, resulting in 74 pregnancies and 44 deliveries (6.7% per aspiration).

Intra-uterine inseminations {#s3j}
---------------------------

Table [IV](#DES023TB4){ref-type="table"} provides data on IUI-H and IUI-D, reported by 23 countries (one more than in 2006), with 1 country reporting only donor insemination (Sweden), whereas 5 countries did not report/practice IUI-D (Albania, Bosnia, Italy, Lithuania and Serbia). Table IVIntrauterine insemination with husband (IUI-H) or donor (IUI-D) semen in 2007.CountryIUI-HIUI-DCyclesDeliveriesDeliveries (%)Singleton (%)Twin (%)Triplet (%)CyclesDeliveriesDeliveries (%)Singleton (%)Twin (%)Triplet (%)Albania36411.1100.00.00.00AustriaBelgiumBosnia1082119.485.79.54.8Bulgaria846728.590.39.70.02113215.290.69.40.0CyprusCzech RepublicDenmark9176111212.186.113.80.2625474912.090.09.90.1Finland37823188.493.76.00.382211213.693.86.30.0France49 240492310.088.111.40.5430766115.386.413.00.6GermanyGreece93612313.197.62.40.02343615.4100.00.00.0Hungary21122039.682.315.82.01762815.982.117.90.0IcelandIreland121713811.390.68.70.71703922.982.110.37.7Italy31 55120766.688.210.71.1Latvia3664Lithuania610Macedonia773536.990.69.40.033721.285.714.30.0MontenegroNorway380359.296.93.10.01652615.884.615.40.0Poland553456510.293.66.20.2113916214.293.86.20.0Portugal17191528.888.211.80.02365021.284.014.02.0Russia369746512.689.89.80.4153423315.288.011.11.0Serbia161127.591.70.08.3Slovenia625416.692.74.92.48112.5100.00.00.0Spain22 91720599.084.814.50.6591783114.086.612.80.6Sweden4927214.6SwitzerlandThe NetherlandsTurkeyUkraine13651259.293.65.60.874113918.892.87.20.0United Kingdom5788358542311.892.76.90.5All^a^142 609124979.288.011.40.626 088360113.889.010.50.5[^15][^16][^17]

For non-donor insemination (IUI-H), 142 609 cycles were reported (+8348), the main contributors being France, Italy and Spain. Among the countries reporting deliveries, the mean delivery rate was 9.2% per cycle (+0.7), 11.4% of deliveries being twin (+0.8%) and 0.6% triplet deliveries (−0.2%).

For donor insemination (IUI-D), 26 088 cycles were reported (+1749), the main contributors being Denmark, Spain and France. The delivery rate was 13.8% per cycle (+1.4%), with multiple delivery rates similar to IUI-H.

Data were also divided in two female age groups, below 40 years (upper panel) and 40 years or more (lower panel), both for IUI-H ([Supplementary data, Table SXVI](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1)) and IUI-D ([Supplementary data, Table SXVII](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1)). For France, stratification for age was not possible. The delivery rate associated with IUI-H declined with age (10.2% below 40 years versus 6.3% above), and the multiple delivery rate decreased slightly from 11.7 to 9.9% for twins, and from 0.5 to 0.0% for triplets. Similar findings were seen in IUI-D, where delivery rates decreased from 14.6 to 6.1%, twin deliveries from 10.2 to 6.5%, and triplets from 0.5 to 0.0%.

Cumulative delivery rates {#s3k}
-------------------------

[Supplementary data, Table SXVIII](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1) gives an estimation of the cumulative delivery rates per initiated fresh stimulated cycle. This is not the true cumulative delivery rate per couple per cycle but shows the number of deliveries obtained from the FER cycles added to the deliveries from the stimulated cycles during the same year. Additionally, the table shows the rate of multiple deliveries after the 'fresh' cycles and the FER combined. It shows that adding the deliveries after FER increases the delivery substantially (Finland +11.8%, Iceland +12.8%, Sweden +7.7% and Switzerland +9.2%). The overall multiple delivery rate was particularly low in Sweden and Finland: 5.3 and 10.9%, respectively, with relatively high cumulative DR (29.7 and 32.5%).

Discussion {#s4}
==========

The present report is the 11th consecutive, annual European report on ART data. Together, these reports cover treatment cycles from 1997 to 2007. It can be argued that as long as data are incomplete, lack uniformity in terms of clinical definitions and are generated through different methods of data collection, they should be interpreted carefully, and the focus should primarily be on specific country data. Nevertheless, summary data reveal important trends in practice and outcomes.

As seen in the tables, registers from a number of countries have been unable to provide some of the data. In order to standardize definitions and reporting, the ICMART (International Committee for Monitoring Assisted Reproductive Technologies) glossary has been published ([@DES023C18],[@DES023C19]), and recently revised with the World Health Organization ([@DES023C20],[@DES023C21]). It is likely that these recommendations were not perfectly implemented in all reporting countries in 2007, meaning that, as in every registry report, the data must still be interpreted with some caution.

In 2007, the number of countries reporting to ESHRE\'s EIM Consortium increased to 33, covering the whole of Western Europe. Bosnia joined the consortium from this year but reporting was patchy in Eastern and South Eastern Europe. No data were available from Estonia, Romania and Slovakia, and Croatia was unable to provide data for 2007.

In 2007, the coverage was 86.0% of all clinics---a figure similar to 2006. However, the coverage was still low in a few countries, such as Greece (9 of 50 clinics), Poland (17 of 38 clinics) and Spain (111 of 182 clinics). The implementation of new regulations may result in an improvement in the coming years.

Overall, the number of reported cycles increased by 7.8% since 2006---reaching a total of 493 184. This was due an overall increase in ART, rather than more intensive coverage, as participation remained at the same level and only a few cycles were contributed by the new country that joined the Consortium. The present report also includes data from almost 169 000 IUI cycles---9000 more than in 2006. Within Europe, the largest numbers of ART cycles were reported from France (68 000), Germany (62 000), Spain (55 000), the UK (47 000) and Italy (44 000). Elsewhere in the world in 2007, 138 198 cycles were reported from the USA ([@DES023C2]), and 56 817 cycles from Australia and New Zealand ([@DES023C1]).

Reduction in the re-imbursement for ART had resulted in a sharp decline in the number of cycles from Germany between 2003 and 2005 (from 102 000 to 53 000). There has been a slow but gradual increase since then up to 62 000 cycles. The German example provides good evidence that a public re-imbursement policy of ART has a major impact on the number of treatments.

As shown in Table [I](#DES023TB1){ref-type="table"} in countries with a full report, the average number of treatment cycles per million inhabitants ranged from 397 in Montenegro to 2558 in Denmark. A better way to define the availability of ART is to report ART cycles in women of reproductive age (15--49 years), which eliminates the impact of age differences across the countries (Table [I](#DES023TB1){ref-type="table"}). Again, there were huge differences, from 1944 cycles per million women in Turkey, to 14 067 in Denmark (Table [I](#DES023TB1){ref-type="table"}). Finally, the percentage of newborns conceived through ART varied from 0.5% in Turkey to 4.9% in Denmark ([Supplementary data, Table SI](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1)). It is difficult to explain those differences which may be related to several factors, such as cost, reimbursement, legal or social aspects, as well as medical strategies relating to the use of ART. These issues also may play a role in the differences observed in pregnancy and delivery rates between countries.

A further question relates to the choice of a suitable denominator in reporting outcomes per cycle. There is general agreement in favour of reporting the number of deliveries (or clinical pregnancies) per initiated cycle. However, from [Supplementary data, Tables SIV and SV](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1), it can be noticed that the cancellation rate (average 8.4% for IVF and 5.9% for ICSI) shows huge variations (from 0 to 17%), making it difficult to compare outcomes of started cycles. Efforts still need to be made to better register initiated cycles if we want to analyse this marker.

The proportion of ICSI versus conventional IVF procedures continues to increase (49% in 2004, 66.5% in 2006 and 68% in 2007). A similar trend has been observed in the USA ([@DES023C14]). As recently reviewed, the trend towards increased use of ICSI has been observed throughout the world ([@DES023C15]; [@DES023C13]). In Australia and New Zealand, 61.8% of all cycles used ICSI in 2007 and in the USA the corresponding figure was 63%, so there is a uniform development in those three regions. However, within Europe a marked variation exists regarding the distribution between IVF and ICSI. As can be seen in Table [I](#DES023TB1){ref-type="table"}, 11 countries used ICSI in more than 75% of cases, the highest being Turkey (97.8%). In contrast, in the Nordic countries, the Netherlands, Russia, Ireland, the UK, and a few other countries, IVF remain the dominant technology. As recently analysed ([@DES023C15]), the marked increase in the use of ICSI cannot be explained by a similar increase in male infertility but rather to a more liberal use of this technique in cases with mixed caused of infertility, unexplained infertility, mild male factor infertility and fertilization failures. Thus, the observed differences can be at least partly explained by differences in professional strategies and clinical decision making.

The trend towards the transfer of fewer embryos was no longer observed in 2007 and cycles where three or more embryos were transferred increased from 20.6 to 25.2% (Table [III](#DES023TB3){ref-type="table"}). The mean percentage of SETs decreased from 22.1% in 2006 to 21.4%, and the proportion of DETs decreased by almost 4% since 2006. However, these findings were mostly explained by the inclusion of data from Turkey, which contributed a large number of treatment cycles. Turkey had not reported the number of transferred embryos in 2006 but, in 2007, 52.8 and 11.7% of transfers involved three and four or more embryos. Exclusion of these data reveals the overall percentages of transfers of 1, 2, 3, and 4 or more embryos to be 22.8, 57.5, 18.5, and 1.2%, respectively, which are more in keeping with the trend seen over the last 10 years.

The same explanation can be given for the increase in multiple pregnancies (21.3% twins and 1.0% triplets). When recalculating data after excluding Turkish ART data, the mean percentages were 20.5 and 0.8%. Thus, the remarkable reduction in triplet deliveries observed previously may persist (3.6% in 1997 to 0.8% in 2007).

There are clearly many differences across the countries. As seen in Table [III](#DES023TB3){ref-type="table"}, five countries reported transfer of a SET in more than 45% of all transfers (one more than in 2006): Sweden (69.9%), Finland (57.8%), Belgium (50.2%), Bosnia (49.6%) and Iceland (46.6%), all with an increase from 0.3 to 11.5% since 2006. In contrast, more than 10% of transfers involved four or more embryos in seven countries (Bosnia, Bulgaria, Greece, Macedonia, Montenegro, Turkey and Ukraine), and the transfer of three embryos reached 58% in Greece, 53% in Turkey and 49% in Italy. This resulted in 4.1 and 32.9% triplet and twin deliveries in Turkey.

In comparison with the situation in Europe, data from other registers show that SET was performed in 63.7% of cycles in Australia and New Zealand ([@DES023C1]), and in 9.4 and 13.1% of transfers at Day 3 and 5, respectively, in the USA ([@DES023C2]).

This report is unable to discriminate between elective SET (eSET) versus SET in general but the rise in the number of transfers of one embryo is undoubtedly related to a rise in eSET and not a rise of cycles with only one embryo obtained.

As evident from Table [III](#DES023TB3){ref-type="table"}, major differences in triplet rates are still evident across countries. We have included data describing preterm birth rates according to the number of fetuses of the pregnancy ([Supplementary data, Table SXIV](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1)), which was provided by 15 countries. The risk of extreme preterm birth (\<28 weeks) was increased 3-fold for twins and by almost twelve fold for triplets. The risk of very preterm (28--32 weeks) birth was increased almost four for twins and 13-fold for triplets.

Fetal reductions are always performed in triplet or higher order gestations. Thus, when analysing the range of triplet delivery rates in different countries, the number of fetal reductions should also be considered. A total of 364 procedures were reported (82 fewer than in 2006). However, the total number is likely to be an underestimate since several countries, including large countries such as France, Germany and the UK, did not report fetal reductions in 2007. Without this intervention, the proportion of triplet deliveries would have been much higher than the number of recorded triplet deliveries (615 in total), given that a number of countries did not report on fetal reductions.

Finally, delivery rates per aspiration showed a marginal increase for IVF (21.9%) and ICSI (19.9%) compared with figures from 2006 (21.5 and 18.4%), as did the delivery rate per thawing for FER (13.5% in 2007 versus 12.7% in 2006).

The delivery rates in Europe remain lower than in the USA where 33.3 and 32.5% of aspirations for IVF and ICSI, respectively, from non-donor cycles resulted in a delivery ([@DES023C2]).

However, the delivery rates in Europe are very similar to those achieved in Australia and New Zealand, where the delivery rate per transfer was 23.9% after fresh cycles and 16.0% after FER transfers in 2007 ([@DES023C1]).

The effect of women\'s age on treatment outcome has been reported since 2006. In 2007, the pregnancy rates per initiated IVF cycle decreased from 34.0% in women aged less than 35 years, to 13.9% in those aged 40 years or more ([Supplementary data, Table SVIII](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1)). Similar trends were noted for ICSI (from 33.3 to 12.2%, [Supplementary data, Table SIX](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1)) and FER (from 21.7 to 14.4%, [Supplementary data, Tables SX](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1)), but not for ED ([Supplementary data, Table SXI](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1)). These supplementary tables also provide delivery rates per cycle. It is important to consider these tables since they better allow comparing the countries, as age is a major prognostic factor that is unequally distributed across the countries.

With the noticeable decline in the number of embryos transferred, the cumulative delivery rate per started cycle may be a most relevant end-point for ART ([Supplementary data, Table SXVIII](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/des023/-/DC1)). In fact, the present method of calculation of this cumulative delivery rates is methodologically flawed because it represents the sum of fresh and FER pregnancies obtained in the same calendar year, rather than the FER pregnancies accruing from a single oocyte aspiration procedure. It should, however, be stressed that the precise figure, which can only be obtained a few years after the initial oocyte aspiration, is likely to be rather similar to our estimate. In several countries, the addition of FER deliveries contributed a substantial increase to the delivery rates per cycle: Finland (20.7--32.5%), Iceland (22.4--35.2%), Sweden (22.0--29.7%) and Switzerland (18.6--27.8%), justifying their transfer and freezing policies.

PGD/PGS activity was recorded from 14 countries, and included 4638 cycles resulting in 706 deliveries (15.2% per aspiration). Detailed analysis of PGD/PGS in Europe will be published separately by ESHRE\'s PGD Consortium ([@DES023C17]).

The major differences between countries in terms of the provision of certain techniques, such as ED and PGD, must be viewed as markers of cross-border reproductive care where couples who do not have access to ART in their home countries, travel elsewhere for treatment. This phenomenon raises important public health concerns and underlines the need for more information in order to facilitate a detailed evaluation. This will be addressed by EIM in the coming year.

Regarding direct risks of ART, OHSS was recorded in 0.7% of cycles, at the same level as in 2006 (0.8%). However, there may be a degree of under-reporting, since the rate varies between 0.3 and 13% in the countries reporting OHSS.

For the sixth consecutive year, the present report includes European data on treatments with IUI-H (143 000 cycles) and IUI-D (26 000 cycles), thus showing an increase in IUI-H (+8000) and in IUI-D (+2000), compared with 2006. The coverage of IUI activities by the national registers is less comprehensive than for the *in vitro* techniques. In women below 40 years of age the delivery rate was 10.2% for IUI-H and 14.6% for IUI-D.

After IUI (both partner and donor insemination), twin pregnancies were observed in approximately half as many cases when compared with IVF/ICSI but triplet rates were comparable.

In summary, the present 11th ESHRE report on ART for Europe in 2007 shows a continuing expansion of numbers of participating clinics, countries and treatment cycles reported. The rise in the use of ICSI continued and reached 68.0% in 2007. Delivery rates after IVF and ICSI increased marginally in comparison with figures from 2006, with minor differences in the number of embryos transferred per cycle and rates of multiple birth.
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Authors\' roles {#s6}
===============

V.G. and J.M. made the calculations. J.M. wrote the paper. All other co-authors reviewed the document and made appropriate corrections and suggestions for improving the document. Finally, this document represents a really collaborative work.

Funding {#s7}
=======

Funding to pay the Open Access publication charges for this article was provided by the European Society of Human Reproduction and Embryology (ESHRE).

Conflict of interest {#s8}
====================

None declared.

Supplementary Material
======================

###### Supplementary Data

Contact persons representing data collection programmes in participating European countries, 2007 {#s9}
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Albania {#s9a}
-------

Prof. Orion Glozheni, University Hospital for Obst & Gynecology, Obsterics & Gynecology. Bul. B. Curri, Tirana, Albania. Tel: +355-4-235-870; Fax: +355-4-257-688; E-mail: <gliorion@icc-al.org>.

Austria {#s9b}
-------

Prof. Dr Heinz Strohmer, Kinderwunschzentrum Private Hospital Goldenes Kreuz, Lazarettg, 16-18, 1090 Wien, Austria. Tel: +43-1-40111-1400; Fax: +43-1-40111-1401; E-mail: <heinz.strohmer@kinderwunschzentrum.at>.

Belgium {#s9c}
-------

Dr Kris Bogaerts, I-Biostat, Kapucijnenvoer 35 bus 7001, 3000 Leuven, Belgium. Tel: +32-16-33-68-90; Fax: +32-16-33-70-15; E-mail: <Kris.Bogaerts@med.kuleuven.be>.

Bulgaria {#s9d}
--------

Prof. Stanimir Kyurkchiev, Inst. Biology & Immunology of Reproduction, Molecular Immunology, 73, Tzaritgradsko shosse, 1113 Sofia, Bulgaria. Tel: +359-2-723-890; Fax: +359-2-720-925; E-mail: <kyurkch@hotmail.com>.

Cyprus {#s9e}
------

Dr Michael Pelekanos, Fertility Centre Aceso, 1, Pavlou Nirvana str., 3021 Limassol, Cyprus. Tel: +357-99645333; Email: <Pelekanos@akeso.com>.

Czech Republic {#s9f}
--------------

Dr Karel Rezabek, Charles University Prague, Gyn/Ob departement, Apolinarska 18, 12000 Prague, Czech Republic. Tel: +420-271028301; Email: <krezabek@vfn.cz>.

Denmark {#s9g}
-------

Dr Karin Erb, Fertility Clinic, Odense University Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark. Tel: +45-65-41-23-24; Fax: +45-65-90-69-82; E-mail: <Karin.erb@ouh.regionsyddanmark.dk>

Finland {#s9h}
-------

Dr Mika Gissler, Nat. Reasearch and Develop. Centre for Wa, P.O. Box 220, 00531 Helsinki, Finland. Tel: +385-9-39672099; Fax: +385-9-9672459; E-mail: <mika.gissler@thl.fi>.

France {#s9i}
------

Dr Jacques de Mouzon, INSERM, 15, Rue Guilleminot, 75014 Paris, France. Tel: +33-1-5841-2268; Fax: +33-1-5841-1539; E-mail: <jdemouzon@noos.fr>; <jacques.demouzon@inserm.fr>.

Prof. Dominique Royère, Agence de la Biomédecine, 1 Av du stade de France, 93212 Saint-Denis La Plaine Cedex, France. Tel: +33-1-55-93-65-50; E-mail: <dominique.royere@biomedecine.fr>.

Germany {#s9j}
-------

Dr Klaus Bühler, Center for Gynaecology, Endocrinology and Repr Med, Ostpassage 9, 30853 Langenhagen, Germany. Tel: +49-511-97230-40; Fax: +49-511-97230-18; Email: <k.buehler@kinderwunsch-langenhagen.de>.

Greece {#s9k}
------

Prof. Dr Basil Tarlatzis, Papageorgiou Hospital, Unit of Human Reproduction, Periferiakis Odos, Neas Efkarpias, 56403 Thessaloniki, Greece. Tel: +30-231-09-91508; Fax: +30-231-0991510; E-mail: <basil.tarlatzis@gmail.com>.

Hungary {#s9l}
-------

Prof. G. Kosztolanyi, University of Pecs, Dept. of Medical Genetics and Child development, Jozsef A.u 7., 7623 Pecs, Hungary. Tel: +36-7-2535977; Fax: +36-7-2535972; E-mail: <gyorgy.kosztolanyi@aok.pte.hu>.

Iceland {#s9m}
-------

Mr H. Bjorgvinsson, Art Medica, IVF Unit, Baejarlind 12, 201 Kopavogur, Iceland. Tel: +354-515-8100; Fax: +354-515-8103; E-mail: <Hilmar@artmedica.is>.

Ireland {#s9n}
-------

Dr Edgar Mocanu, HARI Unit, Rotunda Hospital, Dublin 1, Ireland. Tel: +35-31-8072-732; Fax: +35-31-8727831; E-mail: <emocanu@rcsi.ie>.

Italy {#s9o}
-----

Dr Guilia Scaravelli, Registro Nazionale Medicalmente Assistita, CNESPS, Instituto Superiore de Sanita, Viale Regina Elena, 299, 00161, Roma. Tel: +39-49904319; Fax: +39-49904324; E-mail: <guilia.scaravelli@iss.it>.

Latvia {#s9p}
------

Dr Maris Arajs, EGV Clinic, Dept. of IVF, Gertrudes Str. 3, LV 1010 Riga. Tel: +371-7-27-81-83, +371-26-55-64-66; Fax: +371-7-31-64-67; E-mail: <maris_arajs@inbox.lv>.

Lithuania {#s9q}
---------

Dr Zivile Gudleviciene, Baltic American, IVF Laboratory, Nemencines rd 54A, 10103 Vilnius, Lithuania. Tel: +370-52342020; E-mail: <zivile.gudleviciene@gmail.com>.

Macedonia {#s9r}
---------

Dr Slobodan Lazarevski, SHOG 'Mala Bogorodica', Londonska 19, 1000 Skopje, Macedonia. Tel: +389-2-30-73-335; Fax: +389-2-30-73-398; E-mail: <dr.lazarevski@mbogorodica.com.mk>

Montenegro {#s9s}
----------

Dr Tatjana Motrenko Simic, Medical Center Cetinje, Human Reproduction, Vuka Micunovica 4, 81310 Cetinje, Montenegro. Tel: +382-86232690; Fax: +382-86231336; Email: <motrenko@t-comm.me>.

The Netherlands {#s9t}
---------------

Dr Cornelis Lambalk, Free University Hospital, Reproductive Medicine, de Boelaan 1117, P.O.Box 7057, 1007 MB Amsterdam, The Netherlands. Tel: +31-20-444-00-70; Fax: +31-20-444-00-45; E-mail: <cb.lambalk@vumc.nl>.

Norway {#s9u}
------

Dr Johan T. Hazekamp, IVF-klinikken Oslo AS, PB 5014 Maj., 0301 Oslo, Norway. Tel: +47-2250-8116; Fax:+47-2320-4401; E-mail: <hazekamp@ivfoslo.nhn.no>.

Poland {#s9v}
------

Prof. Rafael Kurzawa, Pomeranian Medical Academy, Department of Reproductive Medicine and Gynaecology, 2 Siedlecka Street, 72--010 Szczecin, Poland. Tel: +48-91-487-37-55; Fax: +48-91-425-33-12; E-mail: <Kurzawa@ams.edu.pl>.

Portugal {#s9w}
--------

Prof. Dr Carlos Calhaz -- Jorge, Faculdade de Medicina de Lisboa, Human Reproduction Unit - Dept. of Ob/Gyn -- Hosp. de Santa Maria; Av. Prof. Egas Moniz, 1649-035 Lisboa, Portugal. Tel: +351-217-264-229; Fax: +351-217-805-621; E-mail: <calhazjorgec@gmail.com>.

Russia {#s9x}
------

Dr Vladislav Korsak, International Center for Reproductive Medicine, General Director, Liniya 11, Building 18B, Vasilievsky Island, 199034 St-Petersburg, Russia C.I.S. Tel: +7-812-328-2251; Fax: +7-812-327-19-50; E-mail: <korsak@mcrm.ru>.

Serbia {#s9y}
------

Prof. Nebosja Radunovic, Institute for Obstetrics and Gynecology, Visegradska 26, 11000 Belgrade. Tel: +38-111-36-15592; Fax: +38-1113615603; E-mail: <radunn01@gmail.com>.

Slovenia {#s9z}
--------

Dr Tomaz Tomazevic, University Medical Centre Ljubljana, Obstetrics Ginecology Reproduction, Slajmerjeva 3, 61000 Ljubljana, Slovenia. Tel: +386-1-522-60-13; Fax: +386-1-431-43-55; E-mail: <tomaz.tomazevic@guest.arnes.si>.

Spain {#s9aa}
-----

Dr Juana Hernandez Hernandez, Hospital San Millan, Servicio de Ginecologia y Obstetricia, Avda. Autonoma de la Rioja 3, 26001 Logrono, Spain. Tel: +34-94-12-73-077; Fax: +34-94-12-73-081; E-mail: <jhernandezh@telefonica.net>.

Sweden {#s9ab}
------

Dr Per-Olof Karlstrom, Akademiska Hospital, Dept. Of Ob/Gyn, 751 85 Uppsala, Sweden. Tel: +46-611-2838; Fax: +46-211-31611; E-mail: <per-olof.karlstrom@karolinska.se>.

Switzerland {#s9ac}
-----------

Ms Maya Weder, Administration FIVNAT, Postfach 89, 3122 Kehrsatz, Switzerland. Tel: +41-31-819-76-02; Fax: +41-31-819-89-20; E-mail: <administration.sgrm@bluewin.ch>.

Turkey {#s9ad}
------

Prof. Dr Timur Gürgan, Gurgan Clinic, Infertility, Cankaya caddesi, 20 / 3, 06680 Cankaya-Ankara, Turkey. Tel: +90-312-4427404; Fax: +90-312-4427407; E-mail: <tgurgan@gurganclinic.com.tr>.

Ukraine {#s9ae}
-------

Dr Viktor Veselovsky, Clinic of Reproductive Medicine Nadija, 28-A, Andriivskyyuzviz str., 01025 Kyiv, Ukraine. Tel: +380-50-311-47-38; Fax: +380-44-5327-75-99; E-mail: <v.veselovskyy@ivf.com.ua>.

UK {#s9af}
--

Mr Richard Baranowski, Deputy Information Manager, Human Fertilization and Embryology Authority (HFEA), 21 Bloomsbury Street, London WC1B 3HF, UK. Tel.: +44-20-7539-3329; Fax: +44-20-7377-1871; E-mail: <Richard.baranowski@hfea.gov.uk>.

[^1]: EIM Committee 2009--2011: Chairman: J. de Mouzon; Chairman elect: A.P. Ferraretti; Past chairman A. Nyboe Andersen; Members: S. Bhattacharya, J.A. Castilla, V. Korsak, M. Kupka, K.G. Nygren (special advisor). V. Goossens is Science Manager at ESHRE Central Office, Brussels. See also Appendix for contributing centres and contact persons representing the data collection programmes in the participating European countries. ESHRE pages content is not externally peer-reviewed. The manuscript has been approved by the Executive Committee of ESHRE.

[^2]: IVF and ICSI: For Belgium, France, Iceland and Turkey treatment cycles refers to 'aspirations', for Czech Republic and Lithunia it refers to 'transfers'.

[^3]: FER: For France, Iceland, Lithuania and Norway treatment cycles refers to 'transfers'.

[^4]: ED: For Czech Republic and Iceland treatment cycles refers to 'aspirations'.

[^5]: PGD and FOR: For France treatment cycles refers 'transfers'.

[^6]: \*Cycles per million calculated for the countries with 100% clinics participating.

[^7]: The recording of deliveries is incomplete. Data on initiated cycles for IVF and ICSI are not available for Belgium, Czech Republic, France, Iceland, Lithuania and Turkey. Data on aspirations in IVF and ICSI are not available for Austria, the Czech Republic and Lithuania. Data on deliveries for IVF and ICSI are not available for Austria, Cyprus and Turkey. No data on FER available for France, Iceland, Lithuania, Montenegro, Serbia, the Netherlands and Turkey.

[^8]: Proportion of infants born through ART among the total number of births is only computed for countries with 100% participation.

[^9]: ART infants per national births (%): only given for countries with complete coverage.

[^10]: Latvia: data on deliveries removed because not complete.

[^11]: Data on deliveries must be considered with some caution, because of difficulties met by some units/countries in gathering pregnancy outcome.

[^12]: ^a^ART infants also include ED.

[^13]: ^b^Totals refer to these countries where data on aspirations, pregnancies and deliveries were all reported for the given technique.

[^14]: \*Totals refer only to these countries where data on number of transferred embryos and on multiplicity were reported. Transfers: data on transfers not available for Austria, Cyprus, Czech Republic, Lithuania, Norway, Spain and The Netherlands. Belgium: 6 more cycles without data (not included), Russia: 1878 more cycles without data (not included), Switzerland: 1 more cycle without data (not included). FER: for 1 delivery multiplicity is not known. Belgium, IVF + ICSI: for 21 deliveries, multiplicity is not known, FER: for 8 deliveries multiplicity is not known. Russia, IVF + ICSI: for 243 deliveries multiplicity is not known, FER: for 47 deliveries multiplicity is not known. Turkey: underestimation of the deliveries, no data for FER.

[^15]: For the UK: the Human Fertilisation and Embryology Authority only started collecting data for IUI-H from 05/07/2007 onwards. The number of IUI-H cycles submitted for the UK (5788) is therefore not for a full year.

[^16]: Data on deliveries were removed for Lithuania.

[^17]: ^a^Total refers to these countries where data were reported and mean percentage were computed for countries with complete information. IUI-H: For Austria, Belgium, Cyprus, Czech Republic, Germany, Iceland, Montenegro, Sweden, Switzerland, The Netherlands and Turkey, no data available. France: 1187 cycles excluded due to unknown age of women, in 90 deliveries multiplicity is not known. Ireland: one clinic did not provide data. Italy: underestimation of the number of deliveries due to lost follow-up. Norway: in three deliveries multiplicity is not known. Russia: For 24 deliveries multiplicity not known. UK: no data on deliveries. IUI-D: For Austria, Belgium, Bosnia, Cyprus, Czech Republic, Germany, Iceland, Italy, Lithuania, Montenegro, Serbia, Switzerland, The Netherlands and Turkey, no data available. France: for 6 deliveries multiplicity is not known. Russia: For 25 deliveries multiplicity is not known. Sweden: in all 72 deliveries multiplicity is not known.
